Literature DB >> 16857611

HTLV-2 infection in injection drug users in King County, Washington.

Joseph R Zunt1, Ken Tapia, Hanne Thiede, Rong Lee, Holly Hagan.   

Abstract

Human T-cell lymphotropic virus type 2 (HTLV-2) is endemic in injection drug users (IDU), and native American populations in the Americas. Transmission is associated with high-risk injection and sexual practices. A cohort of 2561 IDU in King County, Washington completed 2 study visits over 1 y. HTLV-2 infection was detected in 190 (7.4%) of 2561 IDU, and 13 (7.8 cases per 1000 person-y) incident infections occurred during the study. Prevalent infection was associated with female gender, non-white race, longer duration as IDU, having a tattoo, combined injection of heroin and cocaine, and with serologic evidence of hepatitis B and C infection. Seroconversion was more common in women, and was associated with African American race, heterosexual identity and longer duration as IDU. In conclusion, increased risk of HTLV-2 infection was associated with non-white race, and injection drug of choice, suggesting injection networks may play an important role in transmission of HTLV-2. The high correlation of HTLV-2 infection with HCV infection suggests the major route of transmission in IDU is via injection practices. Additional studies are needed to examine the clinical manifestations of HTLV-2 infection, as well as the clinical and virological manifestations of HTLV-2/HCV coinfection.

Entities:  

Mesh:

Year:  2006        PMID: 16857611      PMCID: PMC2683846          DOI: 10.1080/00365540600617009

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  30 in total

1.  An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users.

Authors:  R C Hershow; N Galai; K Fukuda; J Graber; D Vlahov; G Rezza; R S Klein; D C Des Jarlais; C Vitek; R Khabbaz; S Freels; R Zuckerman; P Pezzotti; J E Kaplan
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

2.  HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators.

Authors:  E L Murphy; J Fridey; J W Smith; J Engstrom; R A Sacher; K Miller; J Gibble; J Stevens; R Thomson; D Hansma; J Kaplan; R Khabbaz; G Nemo
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Retroviral coinfections at a New Orleans HIV outpatient clinic.

Authors:  R Bessinger; M Beilke; P Kissinger; C Jarrott; O F Tabak
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-01-01

4.  Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. HTLV Spanish Study Group.

Authors:  V Soriano; A Vallejo; M Gutiérrez; C Tuset; G Cilla; R Martínez-Zapico; F Dronda; E Caballero; E Calderón; A Aguilera; A M Martín; J Llibre; J del Romero; R Ortiz de Lejarazu; F Ulloa; J Eirós; J González-Lahoz
Journal:  Eur J Epidemiol       Date:  1996-12       Impact factor: 8.082

5.  Myelopathy among Brazilians coinfected with human T-cell lymphotropic virus type I and HIV.

Authors:  L H Harrison; B Vaz; D M Taveira; T C Quinn; C J Gibbs; S H de Souza; J C McArthur; M Schechter
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

6.  Prevalence and epidemiologic correlates of human T cell lymphotropic virus infection among intravenous drug users.

Authors:  J Schwebke; D Calsyn; K Shriver; A Saxon; J Kleyn; E Oluoch-Mitchell; L Olmstead; L D Fisher; M Krone; R Ashley
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

7.  Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, U.S.A.

Authors:  D Vlahov; R F Khabbaz; S Cohn; N Galai; E Taylor; J E Kaplan
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-05-01

8.  Prevalence of HTLV types I and II among drug users in King County, Washington.

Authors:  H Thiede; N V Harris; J P McGough; B Roberts; R F Khabbaz; J E Kaplan
Journal:  West J Med       Date:  1994-06

9.  Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group.

Authors:  D R Henrard; V Soriano; E Robertson; M Gutierrez; J Stephens; F Dronda; F Miles; E Pujol; M Buytendorp; A Castro
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users.

Authors:  A Visconti; L Visconti; R Bellocco; N Binkin; G Colucci; L Vernocchi; M Amendola; D Ciaci
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-11
View more
  4 in total

Review 1.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

2.  The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus.

Authors:  Fabianna Bahia; Vinicius Novais; Jennifer Evans; Chloe Le Marchand; Eduardo Netto; Kimberly Page; Carlos Brites
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08       Impact factor: 3.731

Review 3.  Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs.

Authors:  Erika Castro; Elena Roger
Journal:  World J Virol       Date:  2016-05-12

4.  Evaluation of the Inflammatory Cytokines and IL-10 Network in Individuals Co-infected With Human T-Cell Lymphotropic Virus and Hepatitis C Virus (HTLV/HCV).

Authors:  Felicidade Mota Pereira; Pablo Ivan Pereira Ramos; Monique Lirio; Ajax Mercês Atta; Isabela Silva de Oliveira; Fabio Carneiro Vosqui Nascimento; Marcelo Costa Silva; Bernardo Galvão-Castro; Maria Fernanda Rios Grassi
Journal:  Front Microbiol       Date:  2021-02-26       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.